Interferon-α Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients.

Bone marrow transplantation or ponatinib treatment are currently recommended strategies for management of patients with chronic myeloid leukemia (CML) harboring the T315I mutation and compound or polyclonal mutations. However, in some individual cases, these treatment scenarios cannot be applied. We...

Full description

Bibliographic Details
Published in:	PLoS ONE
Main Authors:	Vaclava Polivkova, Peter Rohon, Hana Klamova, Olga Cerna, Martina Divoka, Nikola Curik, Jan Zach, Martin Novak, Iuri Marinov, Simona Soverini, Edgar Faber, Katerina Machova Polakova
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2016-01-01
Online Access:	https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0155959&type=printable

Similar Items

Distinct pattern of genomic breakpoints in CML and BCR::ABL1-positive ALL: analysis of 971 patients
by: Lenka Hovorkova, et al.
Published: (2024-07-01)

S154: IMATINIB-RESISTANT CLONES ISOLATED FROM A MODEL OF BLAST CRISIS OF CHRONIC MYELOID LEUKAEMIA DIFFER IN MUTATIONS IN BCR::ABL1 AND OTHER CANCER RELATED GENES AND IN THEIR SENSITIVITY TO BH3-MIMETICS
by: A. Laznicka, et al.
Published: (2022-06-01)

S152: COMBINATORY THERAPY OF ASCIMINIB AND PONATINIB WAS EFFECTIVE IN THE TREATMENT OF BLAST PHASE CML CDX MODEL
by: Nikola Čuřík, et al.
Published: (2023-08-01)

CML-like biology: BCR::ABL1 and beyond...
by: Jan Zuna
Published: (2025-10-01)

Evolution of BCR/ABL gene mutation in CML is time dependent and dependent on the pressure exerted by tyrosine kinase inhibitor.
by: Shantashri Vaidya, et al.
Published: (2015-01-01)

BCR-ABL1 Doubling-Times and Halving-Times May Predict CML Response to Tyrosine Kinase Inhibitors
by: Maria Stella Pennisi, et al.
Published: (2019-08-01)

Evaluation of 5‐year imatinib treatment of 458 patients with CP‐CML in routine clinical practice and prognostic impact of different BCR‐ABL cutoff levels
by: Hana Klamová, et al.
Published: (2013-04-01)

Dual EGFR and ABL Tyrosine Kinase Inhibitor Treatment in a Patient with Concomitant EGFR-Mutated Lung Adenocarcinoma and BCR-ABL1-Positive CML
by: Kousuke Watanabe, et al.
Published: (2020-01-01)

BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia
by: Klara Srutova, et al.
Published: (2018-12-01)

Digital PCR for BCR-ABL1 Quantification in CML: Current Applications in Clinical Practice
by: Camille C.B. Kockerols, et al.
Published: (2020-12-01)

Monitoring BCR-ABL transcript levels by real-time quantitative polymerase chain reaction: a linear regression equation to convert from BCR-ABL/B2M ratio to estimated BCR-ABL/ABL ratio
by: Ilaria Iacobucci, et al.
Published: (2007-03-01)

Combined targeting of GPX4 and BCR-ABL tyrosine kinase selectively compromises BCR-ABL+ leukemia stem cells
by: Chengwu Zeng, et al.
Published: (2024-10-01)

Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors
by: Manuela Mancini, et al.
Published: (2022-08-01)

Committed change of real-time quantitative PCR to droplet digital PCR for monitoring BCR::ABL1 transcripts in tyrosine kinase inhibitor treated CML
by: Adcharee Kongruang, et al.
Published: (2023-12-01)

Quantification of Main Bcr-abl Gene Transcripts in CML Patients Using Competitive RT-PCR
by: Ali Nazemi, et al.
Published: (2016-04-01)

Quantification of main bcr-abl gene transcripts in CML patients using competitive RT-PCR
by: Ali Nazemi, et al.
Published: (2016-04-01)

Importance of early and deeper responses to long-term survival in CML patients: Implications of BCR-ABL testing in management of CML in Indian setting
by: Mohan B. Agarwal
Published: (2014-01-01)

Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia
by: Veronica Leoni, et al.
Published: (2015-03-01)

Cross-talk between Bcr-abl and the Thioredoxin System in Chronic Myeloid Leukaemia: Implications for CML Treatment
by: Erin Clapper, et al.
Published: (2020-03-01)

“Preleukemic or smoldering” chronic myelogenous leukemia (CML):BCR-ABL1 positive: A brief case report
by: John M. Bennett, et al.
Published: (2015-01-01)

Development of BCR-ABL1 Transgenic Zebrafish Model Reproducing Chronic Myeloid Leukemia (CML) Like-Disease and Providing a New Insight into CML Mechanisms
by: Daniela Zizioli, et al.
Published: (2021-02-01)

PREDICTIVE VALUE OF QUANTITATIVE RT-QPCR BCR::ABL1 AT DIAGNOSIS AND EUTOS SCORE FOR IMATINIB RESPONSE IN CML PATIENTS
by: DS Oliveira, et al.
Published: (2024-10-01)

BCR-ABL kinase domain mutations in CML patients, experience from a tertiary care center in North India
by: Akhilesh S, et al.
Published: (2024-01-01)

Kinetics of BCR::ABL1 transcript levels and molecular relapse after tyrosine kinase inhibitors discontinuation in chronic myeloid leukemia patients: preliminary results from the DES-CML study
by: Bruna Murbach, et al.
Published: (2024-05-01)

Pyrrolo-1,5-Benzoxazepines Induce Apoptosis in Chronic Myeloid Leukemia (CML) Cells by Bypassing the Apoptotic Suppressor BCR-ABL
by: Margaret M. Mc Gee, et al.
Published: (2001-01-01)

Molecular diagnosis of bcr-abl fusion gene in CML patients using Monoplex-Two Steps- Reveres Transcriptase–Polymerase Chain
by: Maysaa A. Dhahii
Published: (2010-04-01)

A multiple reaction monitoring (MRM) method to detect Bcr-Abl kinase activity in CML using a peptide biosensor.
by: Tzu-Yi Yang, et al.
Published: (2013-01-01)

Correction: ATRA-induced cellular differentiation and CD38 expression inhibits acquisition of BCR-ABL mutations for CML acquired resistance.
by: PLOS Genetics Staff
Published: (2015-03-01)

Treatment with low-dose tyrosine kinase inhibitors due to significant haematologic toxicity in patients with CML with prolonged treatment failure prevents haematologic progression
by: Lucia Vráblová, et al.
Published: (2024-12-01)

The Effect of BCR-ABL Specific Tyrosine Kinase Inhibitors on the Thioredoxin System in Chronic Myeloid Leukemia
by: Erin Clapper, et al.
Published: (2021-05-01)

Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy
by: Benjamin Hanfstein, et al.
Published: (2011-03-01)

Differential vascular endothelial cell toxicity of established and novel BCR-ABL tyrosine kinase inhibitors.
by: Yihua Wang, et al.
Published: (2023-01-01)

Higher prevalence of harbouring BCR::ABL1 in first-degree relatives of chronic myeloid leukaemia (CML) patients compared to normal population
by: Jew Win Kuan, et al.
Published: (2024-06-01)

Unveiling the nephrotoxic profile of BCR‐ABL tyrosine kinase inhibitors: A real‐world experience in Africa
by: Zekarias Seifu Ayalew, et al.
Published: (2024-08-01)

Adverse Reaction Profiles Related to Gastrointestinal Bleeding Events Associated with BCR-ABL Tyrosine Kinase Inhibitors
by: Kei Kawada, et al.
Published: (2022-10-01)

ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia
by: Thomas Ernst, et al.
Published: (2008-09-01)

Pterostilbene downregulates BCR/ABL and induces apoptosis of T315I-mutated BCR/ABL-positive leukemic cells
by: Shohei Kawakami, et al.
Published: (2022-01-01)

BCR-ABL1 Tyrosine Kinase Complex Signaling Transduction: Challenges to Overcome Resistance in Chronic Myeloid Leukemia
by: Gustavo P. Amarante-Mendes, et al.
Published: (2022-01-01)

The Discovery of Novel BCR-ABL Tyrosine Kinase Inhibitors Using a Pharmacophore Modeling and Virtual Screening Approach
by: Ting-Ting Huang, et al.
Published: (2021-03-01)

Combination of venetoclax with BCR-ABL tyrosine kinase inhibitor as a therapeutic strategy for Philadelphia chromosome-positive leukemias
by: Jing-Ying Zou, et al.
Published: (2023-12-01)